Revenue
Margin
Demand
Guidance
Tone
Metrics cut 2
- FY27 revenue growth guidance cut to single-digit decline (from flat)
- FY27 EBITDA margin guidance set at mid-20s (from prior steady-state slightly above mid-20s)
Event Participants
Executives
3 Deepak Jain, Kiran Mazumdar-Shaw, Siddharth Mittal
Analysts
6 Bino Pathiparampil, Kunal Dhamesha, Neelam Punjabi, Sanjay Kohli, Shyam Srinivasan, Surya Patra
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue from Operations | ₹736 crore | -16% YoY; primarily due to absence of Zoetis offtake and attrition of a few research services clients |
| Research Services Mix | 78% of sales | Primary contributor in Q1; faced client attrition in commoditized offerings |
| CDMO Mix | 22% of sales | Lower share reflecting Zoetis impact; focus area for recovery |
| Operating EBITDA | ₹91 crore | Margin of 12%; lower revenues and ₹50 crore FX hedge loss partially offset by cost optimization (employee and other expenses) |
| PAT (before exceptional) | ₹1 crore | Thin profitability reflecting revenue and FX pressures |
| Exceptional Items | ₹10 crore (net of tax) | Termination benefits per company policy |
| Reported PAT | -₹9 crore | Loss after exceptional charge |
| Capex | ~₹70 crore | Primarily Bayview facility plus technology platforms (automation and AI) |
| Net Cash | ₹1,541 crore | Strong balance sheet; sequential decline reflects normal utilization of customer advances |
Geographic & Segment Commentary
- Research Services (Discovery/Development): Accounted for 78% of Q1 revenue. Experienced attrition of clients in commoditized areas (especially discovery chemistry) due to pricing pressure. Management is de-emphasizing low-margin generic work and pivoting to differentiated offerings including AI-enabled platforms, oligonucleotides, ADCs, peptides, translational science and clinical research.
- CDMO (Small & Large Molecule): Contributed 22% of Q1 sales. Large-molecule business significantly impacted by loss of Zoetis (nearly $50 million annual impact). Small-molecule Mangalore facility seeing lock-ins for commercial and clinical molecules with ramp-up expected this year and into FY 2028. Stelis (Unit 3) has signed clinical/development-stage customers with ongoing ramp-up; no large commercial volumes yet. Bayview (US) facility being operationalized by end-FY 2027 with expressions of interest already received.
- Clinical Research & Translational: Small base but grew significantly over the past year under new leadership. MoU signed with Translational Health Science and Technology Institute (THSTI) for early/late-phase clinical development, first-in-human/Phase I programs, bioanalytical and biomarker work. Partnerships in Australia and Europe used to bypass Indian regulatory delays. Expected to become a larger absolute and percentage contributor going forward.
Company-Specific & Strategic Commentary
- Leadership Transition & Course Correction: FY 2027 designated a year of transition, strategic renewal and disciplined execution under new MD & CEO Siddharth Mittal (previously Biocon) with Kiran Mazumdar-Shaw as Executive Chairperson. Abhijit Zutshi (ex-Biocon Generics CCO) appointed to lead commercial organization with sharper segmentation, customer engagement and business development.
- CDMO as Primary Growth Engine: Reaffirming CDMO (especially large-molecule biologics) as long-term growth driver leveraging integrated capabilities from cell-line development to commercial manufacturing plus Bayview US footprint. BIOSECURE Act expected to aid shift of molecules from China.
- Differentiated Discovery & AI: Integrating AI across discovery workflow via SynAI platform (gigascale virtual screening and de-novo design). Expanding emerging modalities and translational/clinical capabilities to move up the value chain and avoid commoditization.
- Sustainability: Recognized for second consecutive year in Time magazine and Statista’s World’s Most Sustainable Companies 2026 ranking (from >5,800 companies across 43 countries).
- Cost Discipline: Ongoing optimization of employee and operating costs (started in FY 2026) plus technology-enabled efficiency; Bayview not expected to be capitalized this year, limiting P&L impact.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Revenue (INR) | Single-digit decline for full FY 2027 | H1 to see significant impact from Zoetis absence; H2 better visibility on both CDMO and discovery; gap filling expected by end-FY 2027 |
| EBITDA Margin | Mid-20s for FY 2027 | Driven by H2 revenue uptake, continued cost savings and normal Q4 seasonality; prior steady-state was slightly above mid-20s |
| Growth Trajectory | Return to profitable sustainable (double-digit) growth from FY 2028 | Mangalore, Stelis and Bayview utilization ramps plus commercial engine and differentiated offerings expected to drive recovery |
| Bayview Facility | Operationalize by end-FY 2027 | Revenues expected to contribute meaningfully from FY 2028; customers already visiting |
| Clinical Business | Strong growth in FY 2027 | From small base; expected to become larger absolute and percentage share over time (no specific % target given) |
Risks & Constraints
| Risk | Context |
|---|---|
| Customer Concentration (Zoetis/Librela) | Loss of major biologics manufacturing contract created significant near-term revenue gap (~$50 million annual impact) and spare capacity; Zoetis not fully zero (small remaining deliveries and inventory for ~2 years) but contribution sharply lower; diversification ongoing but gestation required |
| Commoditization of Research Services | Drift into low-differentiation, price-sensitive discovery chemistry led to client attrition and margin pressure; management deliberately exiting race-to-bottom work while rebuilding higher-value offerings (AI, new modalities) |
| Facility Utilization & Conversion Lag | New capacity (Bayview, Stelis, Mangalore) currently underutilized; RFPs, tech transfers and inspections create time lag before revenue recognition; commercial organization rebuild also has gestation |
| Indian Clinical Trial Regulatory Delays | First-in-human and Phase I/II approvals take significantly longer than in other geographies; mitigated via partnerships in Australia/Europe and industry advocacy, but remains a constraint on domestic acceleration |
| FX Volatility | ₹50 crore hedge loss in Q1 directly compressed margins |
Q&A Highlights
Guidance Revision & Visibility
- Question: What changed between Q4 and Q1 to revise guidance from flat to single-digit de-growth? (Kunal Dhamesha)
- Answer: Primary driver is absence of Zoetis contribution with gap expected to be filled only by end-FY 2027; commercial organization rebuild and RFP-to-revenue gestation also factored; H1 heavier impact, H2 better visibility on CDMO and discovery (Kiran Mazumdar-Shaw, Siddharth Mittal).
Zoetis Gap Fill & Facility Ramps
- Question: Will the commercial-molecule gap be filled by clinical or commercial molecules, and status of Mangalore/Stelis/Bayview? (Kunal Dhamesha, Shyam Srinivasan, Surya Patra)
- Answer: Combination of both; Mangalore has lock-ins for commercial and clinical with significant utilization ramp this year continuing into FY 2028; Stelis is clinical/development stage with ramp underway (no large commercial yet); Bayview operationalization end-FY 2027 with EOIs already converting to projects, revenues mainly FY 2028; green shoots visible but more color next quarter (Siddharth Mittal, Kiran Mazumdar-Shaw).
Discovery Attrition & Differentiation
- Question: Details on clinical-stage client attrition and what is commoditized vs value-added? (Shyam Srinivasan, Kunal Dhamesha)
- Answer: Attrition driven by cost competition in commoditized services (mainly discovery chemistry); deliberately not competing on price; focus shifting to specialized technologies (oligos, ADCs, peptides) and AI-led differentiation with turnaround expected by end-FY 2027 (Kiran Mazumdar-Shaw, Siddharth Mittal).
Clinical Research Opportunity
- Question: Commercial sense of clinical trial activities and potential scale? (Surya Patra, Sanjay Kohli)
- Answer: Attractive emerging segment from small base with significant recent growth under new leadership and THSTI MoU; differentiates via translational, first-in-human and biomarker capabilities; will grow in absolute and % terms but no specific multi-year % target (other businesses also grow); Indian regulatory delays being mitigated via Australia/Europe partnerships (Kiran Mazumdar-Shaw, Siddharth Mittal).
Margin Bridge & Cost Actions
- Question: How to achieve mid-20s EBITDA given 12% in Q1, and cost measures/Bayview impact? (Bino Pathiparampil, Neelam Punjabi)
- Answer: H2 revenue recovery + continued cost optimization (people and opex, technology-enabled) + normal Q4 seasonality; Bayview not capitalized this year so minimal P&L drag; margins expected to improve (not stay flat) in FY 2028 with growth (Deepak Jain, Kiran Mazumdar-Shaw).
Cash Position & Utilization
- Question: Why cash declined from ~₹1,800 crore last year and future strategy? (Neelam Punjabi)
- Answer: Normal seasonal pattern (customer advances received early calendar year, utilized through year); cash will continue to fund investments in Bayview, capabilities and new modalities (Deepak Jain).
Key Takeaway
Syngene reported Q1 FY 2027 revenue of ₹736 crore (-16% YoY) and operating EBITDA of ₹91 crore (12% margin) primarily due to the absence of Zoetis offtake and attrition in commoditized research services, resulting in a reported PAT loss of ₹9 crore after a ₹10 crore exceptional charge; research services contributed 78% and CDMO 22%, with net cash at ₹1,541 crore and capex of ~₹70 crore. Under new MD & CEO Siddharth Mittal and Executive Chairperson Kiran Mazumdar-Shaw, FY 2027 is positioned as a transition year of course correction focused on rebuilding the commercial engine (led by Abhijit Zutshi), elevating CDMO (especially large-molecule biologics and Bayview) as the primary growth engine, differentiating discovery via AI/SynAI and new modalities (oligos, ADCs, peptides), and expanding clinical/translational capabilities via the THSTI MoU. Full-year guidance is a single-digit INR revenue decline and mid-20s EBITDA margins, with H2 recovery expected and return to double-digit profitable growth from FY 2028 as Mangalore, Stelis and Bayview ramp; key watch points remain residual Zoetis exposure, conversion lag on new capacity, and Indian clinical regulatory timelines.